MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Arrowhead Pharmaceuticals Inc

Suletud

SektorTervishoid

12.14 -4.33

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.1

Max

12.9

Põhinäitajad

By Trading Economics

Sissetulek

-1.9M

-175M

Müük

2.5M

2.5M

Aktsiakasum

-1.39

Kasumimarginaal

-7,008.72

Töötajad

609

EBITDA

4.9M

-148M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+218.68% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2025

Turustatistika

By TradingEconomics

Turukapital

1.9B

Eelmine avamishind

16.47

Eelmine sulgemishind

12.14

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Arrowhead Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. sept 2024, 10:38 UTC

Suurimad hinnamuutused turgudel

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Võrdlus sarnastega

Hinnamuutus

Arrowhead Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

218.68% tõus

12 kuu keskmine prognoos

Keskmine 40.6 USD  218.68%

Kõrge 80 USD

Madal 21 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Arrowhead Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

7

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 12.66Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.